Transplantation of miRNA-34a overexpressing adipose-derived stem cell enhances rat nerve regeneration.
He X., Ao Q., Wei Y., Song J.
Animal Study, published in Wound Repair Regen (2016) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Wound Repair Regen (2016)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 26899299
- DOI
- 10.1111/wrr.12427
Abstract (original English)
Peripheral nerve injury is an ongoing challenge in reconstructive surgery. Adipose-derived stem cell (ADSC) application is reported to improve nerve regeneration. In the present study, we evaluated the potential benefit of 34a-ADSCs for never regeneration. Lentiviral vectors containing miRNA-34a were constructed and ADSCs were transduced. The obtained 34a-ADSCs were used to regenerate the sciatic nerve in surgically induced sciatic nerve injury rat model. Sprague-Dawley (SD) rats were randomly divided into two groups, a 34a-ADSC group and an Lv-ADSC group. Functional nerve recovery was assessed by walking track analysis at 12 weeks after surgery. In addition, histology, including light microscopy and transmission electron microscopy, and immunohistochemistry, was utilized to investigate the nerve repair effects of 34a-ADSC. Results showed that reconstruction of the injured sciatic nerve had been significantly enhanced by restoration of nerve continuity and functional recovery in the 34a-ADSC group compared with the Lv-ADSC group. Furthermore, sciatic nerve conduction velocity and compound nerve action potential in the 34a-ADSC group was much higher than that in the Lv-ADSC group (30.72 ± 2.95 m/s vs. 22.73 ± 1.91 m/s, p< 0.0001; 11.93 ± 0.76 mV vs. 9.52 ± 0.53 mV, p = 0.0418). This study raises the possibility of using miRNA-34a overexpressed ADSCs as a promising alternative fo
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.